Zoetis Inc. (ZTS) research
Zoetis Inc.- Sector
- Health Care
- Industry
- Pharmaceuticals
- Last price
- $71.40
- As of
Zoetis Inc. (ZTS): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.
As of . Source: SEC EDGAR filings for ZTS. Method and limitations.
Share the ZTS intelligence card
See ZTS live in the terminal
Track ZTS's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live ZTS terminal, freeActive signals for ZTS
- highCONSENSUS_BUY
12 tracked funds increased ZTS this 2026Q2, institutional consensus
- highCONSENSUS_BUY
7 tracked funds increased ZTS this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +448% to ZTS (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +995% to ZTS (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +1485% to ZTS (2026Q2)
FREE, NO ACCOUNT
Every signal on ZTS, as it fires
You are seeing 5 of 139 signals recorded on ZTS since 2026-05-05.
The five above landed across 2 days. The other 134 were recorded on 5 other days. 130 of the 139 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ZTS (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 98978V103 · 2026Q2 | $229.1M | 0.03% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 98978V103 · 2026Q2 | $130.3M | 0.05% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 98978V103 · 2026Q2 | $100.8M | 0.14% | , |
| D. E. Shaw & Co., Inc.CUSIP 98978V103 · 2026Q2 | $38.6M | 0.02% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 98978V103 · 2026Q2 | $27.8M | 0.02% | , |
| Bridgewater Associates, LPCUSIP 98978V103 · 2026Q2 | $9.6M | 0.04% | , |
| SOROS FUND MANAGEMENT LLCCUSIP 98978V103 · 2026Q2 | $2M | 0.02% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ZTS
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ZTS against its peers
ZTS's net margin of 28.2% ranks in the 93rd percentile of 22 Pharmaceuticals sub-industry peers, fiscal period ending 2025-12-31.
| Metric | ZTS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 9.5B USD | 3.0B USD | 61 | 21 |
| Gross margin | n/a | 72.4% | n/a | 9 |
| Operating margin | n/a | -1.4% | n/a | 18 |
| Net margin | 28.2% | 2.7% | 93 | 22 |
| Return on equity | 80.2% | -3.6% | 98 | 23 |
| P / E | 11.9x | 20.3x | 5 | 9 |
Peers (25): TEVA, VTRS, JAZZ, CORT, AXSM, GSK, BMY, AMRX, LQDA, PFE, NVO, TARS, AMLX, OGN, AZN, NVS, MRK, GPCR, HRMY, SUPN, NKTR, OCUL, BHC, TRVI, NUVB. Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (ZTS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ZTS signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ZTSand get the insider, 13F, options, and confluence read in one view.